Stoke Therapeutics Advances with Strong Q1 2025 Results

Stoke Therapeutics ( (STOK) ) has released its Q1 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Stoke Therapeutics, a biotechnology company specializing in RNA medicine to restore protein expression, is advancing its lead investigational medicine, zorevunersen, for Dravet syndrome, a severe genetic disorder. In its first quarter of 2025, Stoke Therapeutics reported significant progress, including regulatory alignment for a Phase 3 study of zorevunersen and a strategic collaboration with Biogen. The company has secured $380.3 million in cash and equivalents, expected to fund operations into mid-2028, and reported a net income of $112.9 million for the quarter, a significant turnaround from a loss in the same period last year. Key financial highlights include a substantial increase in revenue to $158.6 million, driven by the collaboration with Biogen, and increased research and development expenses related to the advancement of zorevunersen. Looking ahead, Stoke Therapeutics is poised to initiate the Phase 3 EMPEROR study in the second quarter of 2025, with data expected in the second half of 2027, supporting global regulatory filings and potential commercialization.